Gastric Cancer
Conditions
Interventions
None listed
Sponsors
National Cancer Center Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically confirmed adenocarcinoma of the stomach or esophago-gastric junction 2) Patents treated with at least two or more lines of previous chemotherapy 3) Treatment with nivolumab monotherapy started between September 22, 2017 and October 31, 2018 in advanced gastric cancer patients with refractotry to, or intolerant of at least two previous chemotherapy regimens (previous chemotherapy must be refractory) 4) Having at least one measurable target lesion defined by CT or MRI 5) CT judged to be refractory to previous chemotherapy can be the baseline data of nivolumab therapy 6) No prior treatment with anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, or other therapeutic antibodies or pharmacotherapies for the regulation of T-cells 7) No systemic corticosteroids (10 mg/day or more) or immune-suppressants administered concurrently or within 14 days before registration
Exclusion criteria
Exclusion criteria: Synchronous or metachronous malignancies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To explore the prevalence and background of hyperprogressive disease | — |
Secondary
| Measure | Time frame |
|---|---|
| To explore the efficacy of nivolumab such as response, progression free survival and overall survival | — |
Countries
Japan
Contacts
Public ContactMasahiko Aoki
National Cancer Center Hospital Gastrointestinal Medical Oncology Division
Outcome results
None listed